Responses
Regular Abstracts – Part 2
Biomarkers, Immune Monitoring and Novel Technologies
222-B Critical clinical evaluation of plasma to tumor tissue concordance by cancer type using Illumina’s cell-free ctTSO500 commercial liquid biopsy assay
Compose a Response to This Article
Other responses
No responses have been published for this article.
